August 3, 2018
FDA issues warning on azithromycin
Editor's Note
The Food and Drug Administration (FDA) on August 3 issued a warning for azithromycin, saying the antibiotic should not be given long-term to prevent an inflammatory lung condition in patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant.
A clinical trial has found an increased rate of relapse in cancers, including death, in these patients. The FDA is reviewing additional data and will issue recommendations when the review is complete.
Free Daily News
- Quality Improvement: Reduce Specimen Labeling Errors
- Staffing Strategy: Grow Your Middle Management
- Olympus issues voluntary labeling update for bronchoscopes used with laser therapy equipment
- NorthStar Anesthesia scales ASC partnerships in Georgia with transparent, clinician-driven model
- Targeted intraoperative radiation slashes pancreatic cancer recurrence to 5%
- Ambient AI reshapes nursing workflows and boosts patient interaction
- Session: Developing a complex spine and total joint service line program in the ASC
- Session: The importance of having a comprehensive plan to prevent workplace violence in ASCs
- Session: Automate to elevate—Streamlining pre-, postoperative processes for better outcomes in ASCs
- Transparent oversight is key to safe surgical innovation
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement